Cellectis Financials
| ALCLS Stock | EUR 1.54 0.02 1.32% |
Cellectis |
Understanding current and past Cellectis Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cellectis' financial statements are interrelated, with each one affecting the others. For example, an increase in Cellectis' assets may result in an increase in income on the income statement.
Cellectis Stock Summary
Cellectis competes with Innate Pharma, Genfit, Nanobiotix, Adocia, and DBV Technologies. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is based in Paris, France. CELLECTIS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 161 people.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0010425595 |
| Business Address | 8, rue de |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cellectis.com |
| Phone | 33 1 81 69 16 00 |
| Currency | EUR - Euro |
You should never invest in Cellectis without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cellectis Stock, because this is throwing your money away. Analyzing the key information contained in Cellectis' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cellectis Key Financial Ratios
Cellectis' financial ratios allow both analysts and investors to convert raw data from Cellectis' financial statements into concise, actionable information that can be used to evaluate the performance of Cellectis over time and compare it to other companies across industries.Cellectis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cellectis's current stock value. Our valuation model uses many indicators to compare Cellectis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cellectis competition to find correlations between indicators driving Cellectis's intrinsic value. More Info.Cellectis is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cellectis' earnings, one of the primary drivers of an investment's value.Cellectis Systematic Risk
Cellectis' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cellectis volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Cellectis correlated with the market. If Beta is less than 0 Cellectis generally moves in the opposite direction as compared to the market. If Cellectis Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cellectis is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cellectis is generally in the same direction as the market. If Beta > 1 Cellectis moves generally in the same direction as, but more than the movement of the benchmark.
Cellectis February 2, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cellectis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cellectis. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cellectis based on widely used predictive technical indicators. In general, we focus on analyzing Cellectis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cellectis's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 24.76 | |||
| Value At Risk | (4.07) | |||
| Potential Upside | 5.52 |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.